Sam Brusco, Associate Editor06.05.24
Curiteva announced over 1,000 patients have been treated with its novel 3D-printed Inspire cervical trabecular PEEK interbody fusion system. This also marks more than 2,000 Inspire implants placed in patients.
The Inspire cervical system underwent a limited launch in April 2023, followed by full commercialization in July.
The Inspire platform is manufactured with Curiteva’s proprietary, patented fused filament fabrication 3D printer. The additive process creates an interconnected, integrated porous structure across the whole implant to promote osseointegration, improve radiographic assessment, and deliver better biomechanics.
The combination of the HAFUSE nanotech surface treatment and porous PEEK structure creates a hydrophilic, bioactive environment for cell attachment, proliferation, and healing in preclinical animal and in-vitro studies.
“I am seeing CT scans of patients at their three-month follow-up showing bone bridging from endplate to endplate through the porous structure of the device. This is unprecedented in my 40 years of practice,” said Randy Dryer, MD, Curiteva’s medical director. “Other companies have touted a porous PEEK implant, but the Curiteva Trabecular PEEK is forming bone across the entire implant.
Chad Falciani, founder and chairman of the board for Curiteva, added, “We’re extremely proud of this milestone. Surpassing 1,000 procedures and over 2,000 implants within a year of commercialization is a testament to our team’s consistent effort and focus. Next month we will be expanding our Inspire Technology into lumbar, adding momentum to our growth in the quarters to come.”
The Inspire cervical system underwent a limited launch in April 2023, followed by full commercialization in July.
The Inspire platform is manufactured with Curiteva’s proprietary, patented fused filament fabrication 3D printer. The additive process creates an interconnected, integrated porous structure across the whole implant to promote osseointegration, improve radiographic assessment, and deliver better biomechanics.
The combination of the HAFUSE nanotech surface treatment and porous PEEK structure creates a hydrophilic, bioactive environment for cell attachment, proliferation, and healing in preclinical animal and in-vitro studies.
“I am seeing CT scans of patients at their three-month follow-up showing bone bridging from endplate to endplate through the porous structure of the device. This is unprecedented in my 40 years of practice,” said Randy Dryer, MD, Curiteva’s medical director. “Other companies have touted a porous PEEK implant, but the Curiteva Trabecular PEEK is forming bone across the entire implant.
Chad Falciani, founder and chairman of the board for Curiteva, added, “We’re extremely proud of this milestone. Surpassing 1,000 procedures and over 2,000 implants within a year of commercialization is a testament to our team’s consistent effort and focus. Next month we will be expanding our Inspire Technology into lumbar, adding momentum to our growth in the quarters to come.”